echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > NEJM: 1 icodec insulin treatment for type 2 diabetes once a week

    NEJM: 1 icodec insulin treatment for type 2 diabetes once a week

    • Last Update: 2020-12-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Reducing the frequency of insulin injections can help improve the treatment compliance of people with type 2 diabetes, icodec, a long-acting form of insulin that can be given once a week to treat diabetes.
    researchers recently conducted a 26-week randomized, double-blind, Phase II trial with insulin glycerion U100 as a control to see the effectiveness and safety of insulin icodec once a week.
    Patients with type 2 diabetes who had not previously received long-term insulin therapy were involved in the study, with poor blood sugar control, 7.0% to 9.5% of glycified hemoglobin levels, and previously treated with metformin, using or not using dipeptide peptide enzyme 4 inhibitors.
    end of the study was a change in glycation hemoglobin levels from baseline examination to week 26.
    safe endpoints, including adverse events related to hypoglycemia and insulin.
    247 patients were studied with similar baseline characteristics between groups, with an average baseline glycation hemoglobin level of 8.09 percent in the icodec group and 7.96 percent in the insulin insulin glycerin group.
    , at 26 weeks, icodec levels of glycoglobin changed by -1.33% compared to the baseline, compared with -1.15% in the glycine group and 6.69% and 6.87% on average.
    week 26, the difference between groups was -0.18% compared to the baseline. The occurrence of hypoglycemia between
    groups with a severity of 2 levels (blood sugar levels of 54 mg/dL) or 3 levels (severe cognitive impairment) was similar and low: 0.53 events/patient years in the icodec group and 0.46 events/patient-years in the insulin group with a risk ratio of 1.09.
    the differences of insulin-related adverse events between the two groups were not significant, and the rate of hypersensitivity reaction and injection site reaction was low.
    most adverse events are mild and there are no serious adverse events associated with experimental drugs.
    study found that for people with type 2 diabetes, icodec insulin treatment once a week had a similar sugar-lowering effect and safety to insulin glycelin U100.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.